A Trial Investigating the Pharmacokinetic and Safety of NN1250 [insulin degludec] in Subjects With Various Degrees of Renal Impairment and in Subjects With Normal Renal Function.

Trial Profile

A Trial Investigating the Pharmacokinetic and Safety of NN1250 [insulin degludec] in Subjects With Various Degrees of Renal Impairment and in Subjects With Normal Renal Function.

Completed
Phase of Trial: Phase I

Latest Information Update: 31 Jan 2017

At a glance

  • Drugs Insulin degludec (Primary)
  • Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 29 Jun 2012 Actual patient number changed from 16 to 32 as reported by ClinicalTrials.gov.
    • 27 May 2010 Actual patient number (16) added as reported by ClinicalTrials.gov.
    • 27 May 2010 Actual end date (May 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top